Bozzato Elia, Bastiancich Chiara, Préat Véronique
Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Institute Neurophysiopathol, INP, CNRS, Aix-Marseille University, 13005 Marseille, France.
Cancers (Basel). 2020 Dec 22;13(1):9. doi: 10.3390/cancers13010009.
The standard of care therapy of glioblastoma (GBM) includes invasive surgical resection, followed by radiotherapy and concomitant chemotherapy. However, this therapy has limited success, and the prognosis for GBM patients is very poor. Although many factors may contribute to the failure of current treatments, one of the main causes of GBM recurrences are glioma stem cells (GSCs). This review focuses on nanomedicine strategies that have been developed to eliminate GSCs and the benefits that they have brought to the fight against cancer. The first section describes the characteristics of GSCs and the chemotherapeutic strategies that have been used to selectively kill them. The second section outlines the nano-based delivery systems that have been developed to act against GSCs by dividing them into nontargeted and targeted nanocarriers. We also highlight the advantages of nanomedicine compared to conventional chemotherapy and examine the different targeting strategies that have been employed. The results achieved thus far are encouraging for the pursuit of effective strategies for the eradication of GSCs.
胶质母细胞瘤（GBM）的标准治疗方法包括侵入性手术切除，随后进行放疗和同步化疗。然而，这种治疗的成功率有限，GBM患者的预后非常差。尽管许多因素可能导致当前治疗失败，但GBM复发的主要原因之一是胶质瘤干细胞（GSCs）。本综述重点关注为消除GSCs而开发的纳米医学策略以及它们在抗癌斗争中带来的益处。第一部分描述了GSCs的特征以及用于选择性杀死它们的化疗策略。第二部分概述了已开发的基于纳米的递送系统，这些系统通过将其分为非靶向和靶向纳米载体来对抗GSCs。我们还强调了纳米医学与传统化疗相比的优势，并研究了所采用的不同靶向策略。迄今为止取得的结果对于寻求根除GSCs的有效策略而言是令人鼓舞的。
